When we compared cfDNA results with the corresponding primary tumour IHC, we found that six of the eight primary patients on follow-up and all five metastatic patients with amplification in cfDNA had HER2 3+ tumour status (Figure 3A). Here, ERBB2 is linked to neoplasm.